Treatment of Seronegative Autoimmune Hepatitis with Cirrhosis

Diagnostic Considerations

The presence of interface hepatitis with lymphoplasmacytic infiltration, nodular cirrhosis, and negative conventional autoantibodies are indicative of seronegative autoimmune hepatitis, which requires treatment regardless of serological status, according to the European Association for the Study of the Liver 1, 2
The American Association for the Study of Liver Diseases recommends checking serum IgG or total globulin levels, as elevated IgG >1.1x upper limit of normal adds 2 points to simplified diagnostic criteria, and considering anti-SLA antibody testing, as this is the only disease-specific autoantibody for AIH 2, 3
The American College of Gastroenterology suggests verifying negative viral hepatitis markers to add 2-3 points to diagnostic scoring, and assessing AST/ALT and ALP:AST ratio to complete diagnostic scoring 1, 2

The European Association for the Study of the Liver recommends treating seronegative autoimmune hepatitis with standard immunosuppressive therapy consisting of corticosteroids with or without azathioprine, given the presence of interface hepatitis, lymphoplasmacytic infiltration on biopsy, and established cirrhosis 1, 2
The American Association for the Study of Liver Diseases suggests that treatment decisions should be based on histological findings, biochemical activity, and presence of cirrhosis rather than serological markers alone, and that do not withhold treatment based solely on negative conventional autoantibodies 2, 3, 4
The initial induction therapy should include prednisone 30 mg daily and azathioprine 50 mg daily, with monitoring of complete blood count and liver function tests, and target normalization of transaminases and IgG within 6-12 months, according to the American College of Gastroenterology 1, 2, 6

The European Association for the Study of the Liver recommends beginning tapering prednisone after biochemical improvement, reducing by 2.5-5 mg every 2-4 weeks as tolerated, and targeting the lowest effective dose or complete withdrawal 1, 5
The American Association for the Study of Liver Diseases suggests increasing azathioprine to 2 mg/kg daily as prednisone is tapered, and continuing azathioprine indefinitely as maintenance monotherapy if remission is achieved 6

The American College of Gastroenterology recommends lower initial corticosteroid doses may be considered to reduce infection risk, but treatment should not be withheld, and screening for esophageal varices and initiating hepatocellular carcinoma surveillance with ultrasound every 6 months 1, 4
The European Association for the Study of the Liver suggests monitoring for decompensation during treatment, and evaluating for metabolic syndrome components and considering non-alcoholic fatty liver disease overlap if steatotic changes are present 1, 4

The American Association for the Study of Liver Diseases recommends treatment should be lifelong in patients with established cirrhosis at presentation, given the high relapse risk after treatment withdrawal, and monitoring frequency after stabilization should be every 3 months minimum, including complete blood count, liver function tests, and IgG 1, 4, 6
The European Association for the Study of the Liver suggests considering repeat liver biopsy at 12-24 months if biochemical remission is achieved, to assess histological response, and evaluating for incomplete response at 6 months, and considering alternative agents if necessary 1, 2, 7